Skip to main content
Log in

Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The pharmacokinetics and pharmacodynamics of the antiarrhythmic drug, disopyramide, were investigated in 12 volunteers who took 300 mg doses of 3 different capsule preparations and an aqueous oral solution of the drug at 1-week intervals. Concentrations of drug unbound to plasma proteins were measured by a sensitive immunoenzyme assay after ultrafiltration of plasma samples taken serially after dosing. QT interval was measured on serial ECG recordings with correction for changes in heart rate. Unbound concentrations of disopyramide were modelled by an open one-compartment pharmacokinetic model with a zero-order absorption rate and a lag time. There was no significant difference in parameter estimates between the four preparations, except for the lag time, which was significantly shorter for the solution preparation. The saturable protein binding of disopyramide was described by a hyperbolic model including a specific binding site and additional nonspecific binding. The pharmacodynamic relationship between unbound drug concentration and QT prolongation was fit by a simple linear model. This fit was better using unbound concentration of the drug than using total concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. Karim, C. Nissen, and D. L. Azarnoff. Clinical pharmacokinetics of disopyramide.J. Pharmacokin. Biopharm. 10:465–494 (1982).

    Article  CAS  Google Scholar 

  2. B. Whiting, N. H. G. Holford, and L. B. Sheiner. Quantitative analysis of the disopyramide concentration effect relationship.Eur. J. Clin. Pharmacol. 9:67–75 (1980).

    Article  CAS  Google Scholar 

  3. S. M. Bryson, B. Whiting, and J. R. Lawrence. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.Br. J. Clin. Pharmacol. 6:409–419 (1978).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. J. J. Lima, H. Boudoulas, and M. Blanford. Concentration dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.J. Pharmacol. Exp. Ther. 219:741–747 (1981).

    CAS  PubMed  Google Scholar 

  5. G. W. Holt, R. L. G. Norris, P. J. Ravenscroft, J. H. N. Bett, L. G. Dryburgh, and C. M. Boyle. Effect of disopyramide on left ventricular performance: The relationship of free and total concentrations of the drug and of its mono-N-dealkylated metabolite to noninvasive indices of function.J. Cardiovasc. Pharmacol. 5:51–54 (1983).

    Article  CAS  PubMed  Google Scholar 

  6. K. M. Giacomini, S. E. Swezey, K. Turner-Tamiyasu, and T. Blaschke. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.J. Pharmacokin. Biopharm. 10:1–14 (1982).

    Article  CAS  Google Scholar 

  7. P. Hinderling, J. Bres, and E. Garrett. Protein binding and erythrocyte partitioning of disopyramide and its monodeakylated metabolite.J. Pharm. Sci. 63:1684–1690 (1974).

    Article  CAS  PubMed  Google Scholar 

  8. P. J. Meffin, E. W. Robert, R. A. Winkle, S. Harapat, F. A. Peters, and D. C. Harrison. Role of concentration dependent plasma protein binding in disopyramide disposition.J. Pharmacokin. Biopharm. 7:29–46 (1979).

    Article  CAS  Google Scholar 

  9. M. M. Bradford. A rapid sensitive method for quantification of microgram quantities of protein.Anal. Biochem. 72:248–257 (1976).

    Article  CAS  PubMed  Google Scholar 

  10. L. M. Shaw, R. Altman, B. C. Thompson, and L. Fields. Effect of several variables on the in vitro binding of disopyramide to serum proteins.Clin. Pharmacokin. 9:98–99 (1984).

    Article  CAS  Google Scholar 

  11. SYVA Corp., unpublished observations.

  12. B. E. Pape. Enzyme immunoassay of disopyramide in serum.Clin. Chem. 27:2038–2040 (1981).

    CAS  PubMed  Google Scholar 

  13. J. D. Huang and S. Øie. Effect of altered disopyramide binding on its pharmacologic response in rabbits.J. Pharmacol. Exp. Ther. 223:469–471 (1982).

    CAS  PubMed  Google Scholar 

  14. L. B. Sheiner and S. L. Beal. Estimation of pooled pharmacokinetic parameters describing population. In Laszlo Endrenyi (ed.),Kinetic Data Analysis. Plenum Press, New York, 1981, pp. 271–284.

    Chapter  Google Scholar 

  15. N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship.Clin. Pharmacokin. 6:429–452 (1981).

    Article  CAS  Google Scholar 

  16. C. Peck, L. B. Sheiner, and A. I. Nichols. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data.Drug Metab. Rev. 15:133–148 (1984).

    Article  CAS  PubMed  Google Scholar 

  17. W. F. Raub. The PROPHET computer system and resource sharing.Fed. Proc. 33:2390 (1976).

    Google Scholar 

  18. N. H. G. Holford. MKMODEL, a mathematical modelling tool for the Prophet computer system. In H. M. Perry (ed.),Prophet Public Procedures Notebook, Bolt Beranek and Newman Inc., Cambridge, Mass., 1982, pp. 85–145.

    Google Scholar 

  19. G. Schwartz. Estimating the dimensions of a model.Ann. Stat. 6:461–464 (1978).

    Article  Google Scholar 

  20. J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.Clin. Pharmacokin. 2:373–383 (1977).

    Article  CAS  Google Scholar 

  21. M. L. Aito. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide treatment.Br. J. Clin. Pharmacol. 11:369–376 (1981).

    Article  Google Scholar 

  22. B. M. David, B. W. Madsen, and K. F. Ilett. Plasma binding of disopyramide.Br. J. Clin. Pharmacol. 9:614–618 (1980).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. S. M. Bryson, J. R. Lawrence, W. H. Steele, B. C. Campbell, H. L. Elliott, and D. J. Summer. The influence of protein binding on disopyramide clearance.Eur. J. Clin. Pharmacol. 23:453–456 (1982).

    Article  CAS  PubMed  Google Scholar 

  24. R. L. G. Norris, J. T. Ahokas, and P. J. Ravenscroft. Determination of unbound fraction of disopyramide in plasma: A comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.J. Pharmacol. Methods 7:143–149 (1982).

    Article  Google Scholar 

  25. T. N. Tozer, J. G. Gambertoglio, D. E. Furst, D. S. Avery, and N. H. G. Holford. Volume shift and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.J. Pharm. Sci. 72:1442–1446 (1983).

    Article  CAS  PubMed  Google Scholar 

  26. N. H. G. Holford, P. S. Lizak, and J. G. Gambertoglio. Influence of the error model on the estimation of prednisolone protein binding in man. American Society for Clinical Pharmacology and Therapeutics 84th meeting, 1983, San Diego, Calif., Abstract A 49.Clin. Pharm. Ther. 33:201 (1983).

    Google Scholar 

  27. P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokin. Biopharm. 4:199–230 (1976).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported in part by grant NIH G.M. 28072 and the PROPHET project of the NIH Biotechnology Resources Group (Proc. Natl. Comp. Conf. Exp. 43:457, 1974). M. Thibonnier is the recipient of a Merck Company Foundation International Fellowship in Clinical Pharmacology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thibonnier, M., Holford, N.H.G., Upton, R.A. et al. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. Journal of Pharmacokinetics and Biopharmaceutics 12, 559–573 (1984). https://doi.org/10.1007/BF01059552

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059552

Key words

Navigation